SUTRO BIOPHARMA, INC. (STRO) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
SUTRO BIOPHARMA, INC. (STRO)
A forensic read on SUTRO BIOPHARMA, INC. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-22.1
Altman Z-score
Clean
Earnings quality
2
Forensic signals
-223.8%
ROE
$506M
Market cap
SUTRO BIOPHARMA, INC. earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is -22.1, placing it in the Distress zone. 2 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-308%Return on invested capital.Return on invested capital is -308% and slipping from -33% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
14% of revStock-based comp load.Stock-based compensation ran 14% of revenue in FY2025 — about $1.65 per diluted share. Meaningful — reported free cash flow flatters the economics, since SBC is a real cost paid in shares.
Key fundamentals
Net Margin-186.5%
Free Cash Flow$-178.8M
Latest Revenue$102.5M
Revenue Growth YoY+65.2%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on SUTRO BIOPHARMA, INC.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about STRO's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown